New CRISPR gene therapies for sickle cell disease face lingering technology limits

Sickle cell disease causes red blood cells to become stiff and block blood flow. This painful condition affects many people worldwide. A recent narrative review looked at new treatments using CRISPR-Cas9 gene therapies. These tools edit DNA to fix the genetic error causing the disease. The review also examined a specific system called Fanzor. This approach aims to correct the faulty gene in blood stem cells. The hope is that patients can live without painful crises or need for regular transfusions. However, the review highlights a critical issue. Limitations in CRISPR technology persist. This means the tools are not yet perfect for every patient. Some risks or editing errors might still occur. Because this is a review rather than a new trial, it summarizes existing knowledge. It does not report new safety data or specific patient counts. The findings suggest we must be careful. We need more time to ensure these powerful tools are safe for everyone. Until those limits are solved, doctors and patients should proceed with caution.